Skip to main content

Table 2 Prognostic value of basal type breast cancer delineated by two different immunopanels.

From: Does vimentin help to delineate the so-called 'basal type breast cancer'?

Subgroup Hazard ratio (95%CI) p value 5-year survival rate (95%CI) (%) p value (log-rank)
All patients (n = 179)
'CK5/6 or 14 or 17' 1.46 (0.90–2.37) 0.127   0.124
Positive    63.5 (50.7–73.8)  
Negative    75.3 (66.1–82.4)  
Vimentin 1.22 (0.69–2.14) 0.497   0.496
Positive    59.5 (42.1–73.3)  
Negative    73.9 (65.7–80.4)  
'Vimentin or CK5/6 or 1.73 (1.07–2.81) 0.026   0.024
14 or 17'     
Positive    61.5 (49.3–71.6)  
Negative    77.6 (68.2–84.5)  
Triple negative patients (n = 54)
'CK5/6 or 14 or 17' 0.50 (0.21–1.20) 0.122   0.115
Positive    71.8 (54.9–83.3)  
Negative    52.5 (25.2–74.0)  
Vimentin 0.64 (0.28–1.48) 0.297   0.293
Positive    69.0 (48.8–82.5)  
Negative    68.0 (46.1–82.5)  
'Vimentin or CK5/6 or 0.56 (0.22–1.45) 0.234   0.227
14 or 17'     
Positive    78.6 (62.9–88.2)  
Negative    58.3 (27.0–80.1)  
Non-triple negative patients (n = 125)
'CK5/6 or 14 or 17' 2.61 (1.40–4.84) 0.002   0.002
Positive    50.9 (30.7–67.9)  
Negative    77.8 (67.9–84.9)  
Vimentin* 3.26 (1.37–7.77) 0.008   0.005
Positive    25.4 (3.8–56.4)  
Negative    75.2 (66.1–82.2)  
'Vimentin or CK5/6 or 3.04 (1.66–5.56) <0.001   <0.001
14 or 17'     
Positive    47.5 (29.1–63.8)  
Negative    80.1 (70.2–87.0)  
  1. *In a non-triple negative group only 9 patients were positive for vimentin. Thus, results of survival analysis should be regarded as being inconclusive and they are showed for comparative purposes only.